Important Notice for uniQure Investors: Class Action Deadline Approaches
On February 20, 2026, ClaimsFiler, a valuable resource for shareholders, issued a reminder for investors affected by losses exceeding $100,000 regarding a class action lawsuit against uniQure N.V. Investors have until April 13, 2026, to submit lead plaintiff applications. This lawsuit, ongoing in the Southern District of New York, pertains to alleged violations of federal securities laws committed by uniQure and some of its executives during the specific class period from September 24, 2025, to October 31, 2025.
During this time, uniQure assured investors of the likelihood that its key drug candidate, AMT-130, was on track for swift approval from the U.S. Food and Drug Administration (FDA) following a planned Biologics License Application (BLA) submission in early 2026. However, this optimistic outlook took a hit when, on November 3, 2025, the company revealed that the FDA no longer found the data from their Phase I/II studies adequate for BLA submission. This announcement caused a drastic decline in uniQure's stock price, plummeting more than 49% from $67.69 to $34.29 per share on the day of disclosure.
As per the lawsuit titled Scocco v. uniQure N.V., case number 126-cv-01124, investors who bought shares during the class period may be eligible to join the class action. ClaimsFiler has outlined crucial steps for affected investors, urging them to visit claimsfiler.com or reach out via a toll-free number to connect with attorneys who can provide legal advice regarding their options. This service emphasizes the importance of acting promptly to protect one’s investments in the face of corporate misrepresentation.
ClaimsFiler aims to empower retail investors by providing them with tools and information necessary to claim their share in class action settlements, and they offer a free registration to assist in accessing relevant securities cases. Interested investors can also upload their trading data to receive alerts on pertinent legal actions, ensuring they stay informed about their rights and options.
The claims process can be complex, but ClaimsFiler serves as a comprehensive guide through it, helping investors navigate the legal landscape and maximize the recovery of their losses. By making informed decisions and utilizing available resources, investors can strive for justice and compensation in response to the staggering stock drop caused by unexpected disclosures from uniQure.
For further insights into this ongoing situation and to access support, investors are encouraged to visit ClaimsFiler's website. Time is of the essence, and swift action could be key to securing rightful compensation as the deadline looms closer.
During this time, uniQure assured investors of the likelihood that its key drug candidate, AMT-130, was on track for swift approval from the U.S. Food and Drug Administration (FDA) following a planned Biologics License Application (BLA) submission in early 2026. However, this optimistic outlook took a hit when, on November 3, 2025, the company revealed that the FDA no longer found the data from their Phase I/II studies adequate for BLA submission. This announcement caused a drastic decline in uniQure's stock price, plummeting more than 49% from $67.69 to $34.29 per share on the day of disclosure.
As per the lawsuit titled Scocco v. uniQure N.V., case number 126-cv-01124, investors who bought shares during the class period may be eligible to join the class action. ClaimsFiler has outlined crucial steps for affected investors, urging them to visit claimsfiler.com or reach out via a toll-free number to connect with attorneys who can provide legal advice regarding their options. This service emphasizes the importance of acting promptly to protect one’s investments in the face of corporate misrepresentation.
ClaimsFiler aims to empower retail investors by providing them with tools and information necessary to claim their share in class action settlements, and they offer a free registration to assist in accessing relevant securities cases. Interested investors can also upload their trading data to receive alerts on pertinent legal actions, ensuring they stay informed about their rights and options.
The claims process can be complex, but ClaimsFiler serves as a comprehensive guide through it, helping investors navigate the legal landscape and maximize the recovery of their losses. By making informed decisions and utilizing available resources, investors can strive for justice and compensation in response to the staggering stock drop caused by unexpected disclosures from uniQure.
For further insights into this ongoing situation and to access support, investors are encouraged to visit ClaimsFiler's website. Time is of the essence, and swift action could be key to securing rightful compensation as the deadline looms closer.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.